{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifuad4vjyktze225r7wvqcpmmtjo274c7rxjeuuz53zpqaelsf3dq",
    "uri": "at://did:plc:amgpmo7quvdl4rzvmmjibtx6/app.bsky.feed.post/3mjrhtagkq6f2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia3tiwwy4votmafah77h65do27e6pphqm6o5hlj3cdjbrfvqibk4a"
    },
    "mimeType": "image/jpeg",
    "size": 488752
  },
  "path": "/2026/04/17/health/trump-psychedelics-ibogaine.html",
  "publishedAt": "2026-04-18T02:40:47.000Z",
  "site": "https://www.nytimes.com",
  "tags": [
    "Psychedelic and Hallucinogenic Drugs",
    "Mental Health and Disorders",
    "United States Politics and Government",
    "Executive Orders and Memorandums",
    "Research",
    "Therapy and Rehabilitation",
    "Anxiety and Stress",
    "Post-Traumatic Stress Disorder",
    "Drug Enforcement Administration",
    "Food and Drug Administration",
    "Justice Department",
    "Texas"
  ],
  "textContent": "An upcoming executive order is intended to accelerate research into the compounds’ efficacy in treating PTSD, depression and other mental health problems, officials said.",
  "title": "Trump Expected to Loosen Restrictions on Psychedelic Drugs"
}